Introduction
Gastrointestinal bleeding is a considerable source of clinical morbidity and mortality.
The annual incidence is estimated to be up to 40 to 150 cases per 100,000 people,
with an overall mortality between 3 % and 14 % depending on the population considered
[1 ]
[2 ].
Endoscopic management of nonvariceal gastrointestinal bleeding relies on a discrete
variety of endoscopic tools [3 ]. In the past two decades, technologies based on conveying thermal energy through
electrosurgical devices, argon plasma coagulation or radiofrequency have become the
leading endoscopic techniques for ablation of gastrointestinal vascular lesions with
recurrent bleeding, such as gastric antral vascular ectasia (GAVE), radiation proctitis
or angioectasia [4 ]
[5 ]
[6 ]
[7 ].
In a pilot study published in 2017, a novel laser system with a continuous wave mode
and a 2.0-μm wavelength was adopted for the first time to treat complex nonvariceal
upper gastrointestinal bleeding in a real-life endoscopic setting, showing a very
precise photocoagulation effect and an easy handling profile [8 ]. This result was later confirmed in small case series of patients treated for gastrointestinal
angioectasia with a novel dual emission endoscopic laser system using 1.9-μm and 1.5-μm
wavelength [9 ]
[10 ]. These wavelengths combine a very low absorption coefficient for oxyhemoglobin,
with an excellent water absorption coefficient among continuous wave lasers suitable
for endoscopic purposes ([Fig. 1 ]). This leads to a very confined effect, resulting in a precise coagulation and vaporesective
cutting line with reduced risk of thermal injuries ([Video 1 ]).
Fig. 1 Laser absorption coefficient for hemoglobin, oxyhemoglobin and water, according to
different laser wavelengths.
Video 1 Video representation of the photoresection and photocoagulation effect on organic
tissue of the 1.9-/1.5-μm dual emission endoscopic laser treatment, according to different settings and environmental
conditions. Notably, overall power outputs < 5 W have a very superficial effect (i.e ., mucosal “blanching”) when targeting the gastrointestinal mucosa for no more than
2 seconds.
Here, we describe the first multicenter study of the use of a 1.9-/1.5-μm dual emission
endoscopic laser treatment (1.9-/1.5-μm DEELT) system in patients with bleeding vascular disorders in the upper and lower
gastrointestinal tract.
Patients and methods
This was a multicenter observational study on consecutive patients undergoing upper
or lower digestive endoscopy with 1.9-/1.5-μm DEELT, with all of the following inclusion criteria: aged over 18 years, moderate
to severe iron-deficiency anemia (moderate defined respectively as Hb < 12 g/dL in
men and < 11 g/dL in non-pregnant women, severe defined ad Hb < 8 g/dL in men and
non-pregnant women [11 ]
[12 ]
[13 ]) and hemorrhagic gastrointestinal vascular disorders including angioectasia (i.e.
a cluster of capillary dilatation within the mucosal layer), gastric antral vascular
ectasia (GAVE) and radiation proctopathy (RP). Patients with established multiple
sources of gastrointestinal bleeding were also included, according to the real-life
setting of the present study, hereby featuring an intention-to-treat analyses.
Safety and technical success, defined respectively as the absence of adverse events
(AEs) and as the successful ablation of gastrointestinal vascular lesions, were considered
primary outcomes for this study. A successful ablation was achieved when no residual
significant bleeding vascular lesion was visible at the end of each endoscopic treatment.
AEs potentially related to 1.9-/1.5-μm DEELT or to the endoscopic procedure were documented and classified by the local investigators,
according to the American Society for Gastrointestinal Endoscopy lexicon [14 ].
Secondary outcomes were defined as the difference between the values of the lowest
hemoglobin (Hb) at baseline and 1 and 6 months after 1.9-/1.5-μm DEELT, as well as the difference in the mean number of packed red blood cell (PRBC)
units in the 6 months before and after 1.9-/1.5-μm DEELT. A level of 7 g/dL was commonly defined as sufficient for prescribing a packed
red blood cell transfusion; a lower threshold at 8 g/dL was considered for patients
with known cardiovascular disease [15 ].
For each patient, we recorded age, sex, tobacco use, lowest hemoglobin values before
and after 1 and 6 months from 1.9-/1.5-μm DEELT, need for PRBC transfusions during the 6 months before and after 1.9-/1.5-μm DEELT, Charlson comorbidity index [16 ], antiplatelet or anticoagulation therapy and presence of bleeding diathesis.
For each procedure, total power output, lasing time, fiber type and the need for further
endoscopic haemostasis were recorded. A novel and quantitative endoscopic scoring
system was proposed for evaluating the severity of GAVE before and after treatment.
This score took into consideration antral mucosal vascular ectasia surface involvement
(1–30 % = 1 point, 30–50 % = 2 points, > 50 % = 3 points) and the presence of bleeding
(luminal traces of blood + 3 points, evidence of active bleeding after mucosal washing + 5
points). RP was evaluated with a three-item symptom score and endoscopic severity
score, according to Dray et al [17 ].
Endoscopic procedures were performed in three tertiary referral endoscopic centers
in the metropolitan area of Milan, Italy: IRCCS Policlinico San Donato (San Donato
Milanese), ASST Niguarda and Cà Granda Ospedale Maggiore Policlinico (Milan) between
March 2016 and May 2020. Three endoscopists (GET, LD, LE) with expertise in gastrointestinal
bleedings and non-fully trained on 1.9-/1.5-μm DEELT performed all of the procedures.
The 1.9-/1.5-μm DEELT has been carried out using two endoscopic laser systems (Opera and Opera Evo
by Quanta System, Samarate, Italy), allowing either a single or a blended use of 1.9-μm
and 1.5-μm wavelengths delivered through flexible optical fibers (Quanta System),
with a power setting ranging from 0.5 to 40 W under continuous or pulsed modality
([Table 1 ]). These laser systems have been European Community-certified for various medical
uses, including interventional digestive endoscopy. Based on the previous experiences
[8 ]
[9 ]
[18 ], all 1.9-/1.5-μm DEELT procedures were conducted using a continuous emission modality with reusable
flexible optical fibers (core diameter: 272, 365, 550, 600, and 800 μm) ([Table 2 ] and Supplementary Fig. 1 ).
Table 1
Opera Evo technical specifications.
Opera Evo Technical specifications
Laser sources
1.9 μm + 1.5 μm
Average power
Up to 30 W @ 1.9 µm + up to 10 W @ 1.5 μm with 0.5 W incremental step
Treatment mode
Single wavelength or combined emission
Emission mode
Continuous, pulsed and single pulse
Beam delivery
Wide range of flexible silica fibers
Aiming beam
520 nm (adjustable < 5 mW) – Class 3 R
Fiber recognition
RFID System
Laser class
4 (IEC / EN 60825–1:2007)
Cooling system
Closed water circuit/water air exchanger
Electrical requirements
200–230 Vac, 50 /60 Hz, 1.5 kVA | 240 Vac, 50 Hz, 1.5 kVA
Dimensions/weight
49.5 cm (W) × 63.6 cm (D) × 38.3 cm (H)/40 kg transportable by cart
Table 2
Predictable pros and cons of dual emission endoscopic laser treatment versus standard
hemostatic tools in gastrointestinal endoscopy.
DEELT feature
Pros
Cons
Confined photocoagulation effect
Precise ablation of vascular lesion with limited transmural and lateral thermal injuries.
Need for precise targeting of the lesion with the inert laser beam before any laser
treatment.
Contactless energy release
Constant visualization of the targeted mucosa during photocoagulation.
Instability of distant targets during peristaltic wave movements.
Quick ablation of larger lesions in fewer endoscopic sessions.
On demand distance from target.
Precise setting calibration (fiber caliber, 1.9 and/or 1.5 µm power setting)
Tailored action based on both lesion and organ features.
Multiparameter setting option: fiber caliber and power output presetting according
to the predictable endoscope angulation, targeted lesion extension, dry or water immersion
setting, mucosal and submucosal thickness
Dry or water immersion setting.
Cut, ablation and photocoagulation with the same probe.
No gas insufflation
No risk of over-distension leading to tolerance and safety concerns.
–
No electrical circuit
No ancillary electric devices.
Compatible with any implanted electric medical device.
Delivered by 200–1000 µm flexible optical fibers
Compatible with any endoscope working channel.
Progressive stiffness with larger fibers: difficult retroflexion and strict angulation
with core diameter > 550 µm; challenging use with lateral-view scopes for core diameter > 350 µm.
No or very limited impact on aspiration, washing and suctioning capabilities during
the whole procedure.
A sphincterotome can be used to partially bend the optical fiber tip targeting tangential
lesions.
Increased risk of fiber rupture within the endoscopic working channel when stressing
the optical fiber stiffness with strict endoscope angulation.
Laser class 4 main requirements
–
Indoor laser-controlled area with warning signs and labels, dedicated operator’s education
and training, safety goggles, specific standard operating procedures
Device-related costs (power unit and optical fibers)
Comparable with those of other dedicated endoscopic treatment devices (e. g. radiofrequency
ablation).
Considerable additional costs as compared to standard APC.
The endoscopic procedures were conducted following the European safety requirements
for class 4 laser use (International Electrotechnical Commission standards IEC 60825),
including the use of specific safety goggles, indoor laser-controlled area, warning
signs and labels, operator’s education and training, and standard operating procedures.
Data retrieval was performed retrospectively and anonymously at each center every
6 months based on a predefined and shared data set, according to the abovementioned
primary and secondary outcomes. Paired Student t -test was used for the statistical analyses of the difference between continuous matched
variables. Repeated Measure Analysis of Variance (ANOVA) was employed to test null
hypothesis among multiple groups of paired variables. Wilcoxon signed rank test was
used in secondary outcomes subgroup analyses when data distribution was not assumed
to be normally distributed. Univariate and multivariate analyses were employed to
determine possible interactions of covariates on secondary outcomes results. Fisher’s
exact test was employed to test statistical significance in the analysis of contingency
tables. Statistics were performed with the use of R software (R Foundation for Statistical
Computing, Vienna, Austria).
All patients were treated according to best clinical practice and following the ethical
principles of the Helsinki Declaration and all of its amendments. Informed consent
for laser treatment was retrieved before each procedure.
Results
Study population
Fifty consecutive patients underwent 58 1.9-/1.5-μm DEELTs for GAVE (22 patients and 27 procedures), angioectasia (22 patients and 23
procedures) and RP (6 patients and 8 procedures). Within the angioectasia group, five
1.9-/1.5-μm DEELTs were performed in the stomach, five in the duodenum, 11 in the right colon
and two in both the stomach and duodenum. All of the procedures were conducted using
a standard colonoscope for the lower gastrointestinal tract and a standard gastroscope
and/or duodenoscope for the upper gastrointestinal tract.
Median age was 74 years (interquartile range [IQR] 67 to 80, range 47 to 91), median
Charlson comorbidity index was 5.5 (IQR 4 to 7.75, range 0 to 13); 36 of 58 procedures
were performed on men, 23 in cirrhotic patients with portal hypertension and three
in subjects with established multiple sources of gastrointestinal bleeding ([Table 3 ]).
Table 3
Baseline demographic and clinical features. GAVE, gastric antral vascular ectasia;
IQR, interquartile range.
Procedures (patients)
58 (50)
Age
74 (IQR 67–80, range 47–91)
Gender
36 men of 58 procedures [62 %]
Charlson Comorbidity Index
5.5 (IQR 4–7.75, range 0–13)
Antiplatelet drugs
28 of 58 procedures [48 %]
Anticoagulant drugs
16 of 58 procedures [27 %]
Tobacco use
5 of 58 procedures [9 %]
Cirrhosis
23 of 58 procedures [39 %]
Bleeding vascular lesions per procedures (per patient)
27 (22) GAVE; 23 (22) angioectasia; 8 (6) radiation proctopathy
Overall, 12 of 58 procedures were carried out multiple times in four patients according
to multiorgan vascular lesions (one patient with angioectasia), complex disorders
requiring multiple treatment sessions (one patient with GAVE and one with RP), or
very late disease recurrence following successful and complete endoscopic ablation
with Hb normalization (one patient with GAVE received four 1.9-/1.5-μm DEELTs, one every year, after a median follow-up of 11 months, range 9 to 12 months).
Most 1.9-/1.5-μm DEELTs (44/58) were performed in patients on anticoagulant (16) or antiplatelet therapies
(28). Concomitant assumption of acetylsalicylic acid was always tolerated, whereas
anti-P2Y (e. g., Clopidogrel, Prasugrel) or anticoagulant drugs were discontinued
on a patient-tailored risk assessment basis [19 ].
Primary outcomes
All procedures were technically feasible leading to successful ablation of the targeted
gastrointestinal vascular lesion/s, with no incident nor intraprocedural or post-procedural
AEs potentially related to the 1.9-/1.5-μm DEELT technique including bleeding, perforation or necroses. Overall, no surgical
intervention, prolonged hospital stays or hospitalization was required, except for
one case of Staphylococcus aureus endocarditis that appeared 72 hours after 1.9-/1.5-μm DEELT of RP in a hospitalized 74-year-old woman with unrecognized severe heart valve
disease who was later referred for cardiac surgery intervention.
Secondary outcomes
Repeated Measure ANOVA was employed to test for statistical significance for the difference
in lowest hemoglobin levels at 1 and 6 months after the procedure, showing an increase
of 1.77 g/dL at 1 month after 1.9-/1.5-μm DEELT (P < 0.01; 95 %CI 1.08 to 2.46, mean 9.03 versus 10.81 g/dL) and 1.70 g/dL at 6 months
(P < 0.01, 95 %CI 0.97 to 2.43, 9.03 versus 10.74 g/dL) ([Fig. 2 ]). The difference in lowest Hb levels at 1 and 6 months after the procedure was tested
with univariate analysis for the following covariates: age, Charlson comorbidity index,
need for transfusions, antiplatelet therapy, anticoagulant therapy, and treated pathology.
None of these covariates was found to be statistically significant in affecting the
gain or loss of hemoglobin levels.
Fig. 2 Boxplot of the lowest hemoglobin values pre- and post-laser ablation.
The mean number of transfused PRBCs decreased by 2.5 compared to the 6 months before
and the 6 months after 1.9-/1.5-μm DEELT (4.3 versus 1.7 PRBC, P < 0.01, 95 %CI 1.5 to 4.0). Consistently, 60 % of transfused patients (19/32) were
relieved of the need for PRBC transfusion after 1.9-/1.5-μm DEELT, and the per patient blood supply requirement (at least one PRBC per patient)
decreased from 55.2 % (32 /58) to 22.4 % (13 /58, P < 0.01, odds ratio 4.2, 95 %CI 1.78 to 10.40) within the study population.
The endoscopic GAVE severity was evaluated before and 1 month after 1.9-/1.5-μm DEELT in 24 of 27 procedures ([Fig. 3 ]). Median endoscopic improvement settled at a difference of 4 of 8 points from baseline
(5 versus 1: P < 0.01, CI95 % 4.0 to 5.5). Notably, 96.3 % of GAVE (26/27 procedures) were treated
in one unique endoscopic session ([Video 2 ]). Symptoms and severity scores for RP were available in five of eight procedures
and showed an improvement, without a statistically significant variation (mean endoscopic
severity score: 5.8 versus 4.0, P = 0.37; mean symptoms score: 2.6 versus 0.8, P = 0.15).
Fig. 3 Images of gastric mucosa from a patient affected by GAVE treated with 1.9-/1.5-μm DEELT. Note the reduced extent of vascular abnormalities after laser treatment and
residual small ulcers.
Video 2 1.9-/1.5-μm Dual emission endoscopic laser treatment of a wide and actively bleeding GAVE lesion
(with punctate pattern type) in a noncirrhotic 78-year-old man with severe iron-deficiency
anemia. The single endoscopic session was carried out under conscious sedation. Endoscopic
and laboratory follow-up confirmed both endoscopic and clinical remission.
Additional endoscopic and technical parameters
Add-on hemostatic treatment with endoclips was adopted in five of 58 1.9-/1.5-μm DEELT in patients treated for multiple bleeding sources during the same procedure;
this was done as a prophylactic measure rather than for incident persistent bleeding.
All patients tolerated well the endoscopic treatments under conscious sedation, with
intravenous midazolam ± opioids, and no general anesthesia was required.
Endoscopists reported an overall good and rapidly improving confidence in using 1.9-/1.5-μm DEELT, as well as excellent visualization of the mucosal target. The optical fiber
with a core diameter of 550 μm was utilized in 42 of 58 1.9-/1.5-μm DEELT sessions (Supplementary Fig. 2 ).
The settings and technical parameters for the 1.9-/1.5-μm DEELT sessions are provided in [Table 4 ]. No relevant difference in settings and technical parameters was observed among
the three centers involved. When adopted for gastrointestinal segments with a thicker
mucosal/submucosal layer, the laser output was increased to achieved deep photocoagulation
of lesions with a submucosal origin (e. g., GAVE) and induce curative tissue scars
(RP). In contrast, thinner gastrointestinal tract was approached with a more conscious
and conservative laser output presetting to avoid deep transmural damage.
Table 4
Dual emission endoscopic laser treatment: technical parameters.
GAVE
Angioectasia[1 ]
RP
No. procedures
27
23
8
Median laser power output
7 (IQR 6–8)
3 (IQR 3–4)
6 (IQR 5–8)
Median released energy
2002 (IQR 1538–2507)
21 (IQR 13–36)2 ]
1531 (IQR 807–2400)
Median lasing time (seconds)
296 (IQR 238–362)
6 (IQR 4–11)†
266 (IQR 174–295)
GAVE, gastric antral vascular ectasia; IQR, interquartile range.
1 Angectasia distribution: 11 in the right colon (1.9 + 1.5 μm median power output:
3 W + 1 W), 5 in the stomach (1.9 + 1.5 μm median power output: 7 W + 2 W), 5 in the
duodenum (1.9 + 1.5 μm median power output: 5 W + 2 W), 2 in both stomach and duodenum.
2 Five outlier procedures were ruled out due to extensive and prolonged laser ablation
of multiple and large angioectasias significantly affecting final technical parameters
results.
Discussion
The 1.9-/1.5-μm DEELT is a novel endoscopic tool designed to improve hemostatic ablation and resection
of luminal lesions along the entire gastrointestinal tract. The 1.9-μm wavelength
has a precise and confined action on tissues, due to the strong absorption of energy
by molecules of water. In fact, the thulium-doped yttrium-aluminum-garnet laser system,
which shares these specific wavelength features (1.91 to 2.04 μm), is an established
surgical device, especially in the field of urology (prostate vapo-resection, enucleation
and ablation [20 ]
[21 ]
[22 ]
[23 ]
[24 ], bladder tumors [25 ], ureteral and kidney neoplasia [26 ] and stricture [27 ]). This peculiarity limits potential transmural and lateral damage when treating
gastrointestinal mucosa, as confirmed in a preliminary ex vivo histological study
[18 ].
The second wavelength of 1.5 μm produces more pronounce coagulation and has a less
confined effect due to a lower absorption capacity for water ([Fig. 1 ]).
Recent ex vivo and in vivo retrospective pilot studies have shown very promising results
with the use of these lasers in gastrointestinal luminal endoscopy for the treatment
of vascular lesions [9 ]
[10 ], Zenker diverticulum [28 ]
[29 ], lithotripsy [30 ], ablation of preneoplastic lesion, tumor debulking [8 ], mucosal incision, submucosal tunnelling, and dissection [18 ].
This multicenter series of consecutive patients finally confirms both the safety and
the effectiveness of 1.9-/1.5-μm DEELT for gastrointestinal vascular lesions in a real-life clinical scenario. The
endoscopic photocoagulation of mucosal vascular lesions was feasible and successful
with an excellent safety profile in the upper as well as in the lower gastrointestinal
tract. Consistently, patients undergoing 1.9-/1.5-μm DEELT showed quick and sustained restoration of hemoglobin levels and reduced transfusion
support.
Notably, neither technical problems nor safety nor near miss occurred. In addition,
the 1.9-/1.5-μm DEELT technique was reproducible with excellent maneuverability and resulted in substantial
immediate confidence among independent endoscopic operators from their first uses
of the technique and despite limited experience with non-contact devices and laser
systems. Remarkably, 96.3 % of patients with GAVE were treated in one unique endoscopic
session under conscious sedation, confirming the excellent maneuverability and tolerability
of this technique.
The study limitations and the potential role of 1.9-/1.5-μm DEELT in the gastrointestinal setting should be discussed. As far as this real-life
study is concerned, the retrospective design represents a potential source of bias.
To narrow this limitation, a predefined data set was designed a priori, according
to the abovementioned primary and secondary outcomes and data collection was performed
every 6 months at each tertiary endoscopic center. Symptoms and severity scores for
RP failed to demonstrate a statistically significant improvement and this is probably
due to the low number of procedures [8 ]. There is no validated scoring system to assess disease or endoscopic severity of
GAVE yet; consistently, we have designed a quantitative endoscopic scoring system
for evaluating the severity of GAVE before and after treatment, which should later
cross the formal multistep validation process.
Further, we did not make a comparison with standard endoscopic treatment modalities,
hereby shadowing potential predicted benefits of the 1.9-/1.5-μm DEELT option. In fact, even though electrosurgical probes, argon plasma coagulation
(APC) and, to a lesser extent, radiofrequency are well-established tools in modern
endoscopy, they are not free from flaws. Electrosurgical probes need stable contact
with the mucosa, masking the targeted area and potentially leading to lateral or transmural
thermal injury [3 ]. APC is a non-contact device similarly requiring close proximity (2–10 mm) and conveying
energy in a scattered manner across the submucosa and the muscle layer [8 ]
[31 ]
[32 ]. APC might also induce gas over-distension, reducing patient tolerance and raising
safety concerns for prolonged treatments (e. g., GAVE) or fragile segments (e. g.,
cecum) [1 ]
[2 ]. Furthermore, our results on hemoglobin levels at 1 month are comparable to previous
findings of endoscopic treatment GAVE with APC [33 ].
In the present real-life multicenter study, the peculiarities of the 1.9-/1.5-μm DEELT system have shown predictable pros and cons in clinical practice compared with
standard devices for hemostatic ablation along the gastrointestinal tract, as outlined
in reports from previous smaller studies [8 ]
[9 ]
[10 ]
[28 ]
[29 ]
[30 ]
[34 ]
[35 ]
[36 ]
[37 ] ([Table 2 ]). This new generation of lasers suitable for endoscopic therapy has shown a very
confined and adjustable photocoagulative effect as opposed to previous laser devices
for endoscopic thermocoagulation abandoned since the 1990 s for either safety or cost-related
issues. Notwithstanding, the use of a class 4 laser system for clinical activity still
implies additional direct costs and several logistical requirements ([Table 2 ]). In addition, a few technical aspects also should be highlighted. The stiffness
of larger fibers can be an obstacle in cases of strict angulations, tangential lesions
or with the use of lateral-view scopes potentially leading to accidental damage during
fiber advancement over the endoscope working channel or against the gastrointestinal
wall. Unrecognized fiber breakage during laser application can cause laser leakage
with safety hazard. On the other hand, the flexibility of most fibers (up to a core
diameter of 550 μm) allows laser treatments during endoscope retroversion and use
of ancillary devices such as a sphincterotome to partially bend the optical fiber
tip targeting tangential lesions. This small caliber does not require large operative
channel endoscopes, thereby enabling aspiration, suction and washing during the entire
procedure (especially in comparison with large-caliber hemostatic systems). Moreover,
the green inert lasing beam helps the endoscopist both to target easier the lesion
and to adjust and find the best distance for 1.9-/1.5-μm DEELT.
Conclusions
Taken together, this multicenter study conducted in a real-life scenario confirms
the safety and effectiveness profile of the novel 1.9-/1.5-μm dual emission endoscopic
laser treatment in patients with bleeding vascular disorders in the upper and lower
gastrointestinal tract, thus paving the way for randomized clinical trials, including
with standard endoscopic hemostatic tools.
